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ABSTRACT
Citral, eucalyptol, and linalool are widely used as flavorings,
fragrances, and cosmetics. Here, we examined their effects on
electrophysiological and binding properties of human 5-HT3
receptors expressed in Xenopus oocytes and human embryonic
kidney 293 cells, respectively. Data were analyzed using non-
linear mixed-effects modeling to account for random variance in
the peak current response between oocytes. The oils caused an
insurmountable inhibition of 5‐HT–evoked currents (citral IC50 5
120 mM; eucalyptol 5 258 mM; linalool 5 141 mM) and did not
compete with fluorescently labeled granisetron, suggesting a
noncompetitive mechanism of action. Inhibition was not use‐
dependent but required a 30-second preapplication. Com-
pound washout caused a slow (∼180 seconds) but complete
recovery. Coapplication of the oils with bilobalide or diltiazem
indicated they did not bind at the same locations as these
channel blockers. Homology modeling and ligand docking
predicted binding to a transmembrane cavity at the interface of
adjacent subunits. Liquid chromatography coupled to mass
spectrometry showed that an essential oil extracted from Lippia
alba contained 75.9% citral. This inhibited expressed 5‐HT3
receptors (IC50 5 45 mg ml
21) and smooth muscle contractions
in rat trachea (IC50 5 200 mg ml
21) and guinea pig ileum (IC50 5
20 mg ml21), providing a possible mechanistic explanation
for why this oil has been used to treat gastrointestinal and
respiratory ailments. These results demonstrate that citral,
eucalyptol, and linalool inhibit 5-HT3 receptors, and their binding
to a conserved cavity suggests a valuable target for novel
allosteric modulators.
Introduction
The natural oils citral, eucalyptol, and linalool (Fig. 1) are
widely used as scents and flavorings in pharmaceuticals,
foods, and health care products. Related compounds are
reported to have antioxidant, anti-inflammatory, antiprolifer-
ative, antimicrobial, and acaricide activities. They belong to
the terpenoid class of molecules that contains both structur-
ally complex (e.g., bilobalide and ginkgolide) and simple (e.g.,
thymol and menthol) compounds (Caputi and Aprea, 2011).
Terpenoids have effects on a broad selection of both voltage-
gated and ligand-gated ion channels, and some are noncom-
petitive ligands of 5-hydroxytryptamine 3 (5-HT3) receptors
(Hall et al., 2004; Ashoor et al., 2013; Kessler et al., 2014;
Lansdell et al., 2015; Ziemba et al., 2015).
5-HT3 receptors belong to the Cys-loop family of trans-
membrane ligand-gated ion channels, which are responsible
for fast excitatory and inhibitory neurotransmission in the
central and peripheral nervous systems. It includes vertebrate
nicotinic acetylcholine, GABA and glycine receptors, invertebrate
receptors such as the glutamate-gated chloride channel
(GluCl) and resistance-to-dieldrin channels (RDL), and
prokaryotic homologs such as Erwinia chrysanthemi
ligand-gated ion channel (ELIC) and Gloeobacter violaceus
ligand-gated ion channel (GLIC) (Thompson et al., 2010). Each
channel comprises five subunits surrounding a central ion-
conducting pore, and each subunit has three distinct domains
referred to as extracellular, transmembrane, and intracellu-
lar. The orthosteric binding site (that occupied by endoge-
nous agonist) is located in the extracellular domain at the
interface of two adjacent subunits, where binding is coordi-
nated by the convergence of six peptide loops (Hassaine et al.,
2014). The transmembrane domain of each subunit contains
four a-helices (M1–M4), with M2 from each forming a central
ion-conducting pore; to aid comparisons of the channel-lining
residues of M2 from different Cys-loop receptors, a prime
notation is often used to define residue positions, with 0’
representing a conserved charged residue at the cytoplasmic side
of the membrane. The intracellular domain regulates receptor
trafficking, intracellular modulation, and ion channel conduc-
tance, but remains structurally unresolved (Hassaine et al., 2014).
5-HT3 receptor ligands typically target extracellular and trans-
membrane domains. Competitive antagonists such as granisetron
A.J.T. was supported by the British Heart Foundation (Grant PG/13/39/30293).
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ABBREVIATIONS: BB, bilobalide; DMEM, Dulbecco’s modified Eagle’s medium; DTZ, diltiazem; ELIC, Erwinia chrysanthemi ligand-gated ion
channel; G-FL, granisetron-fluorescein; GLIC, Gloeobacter violaceus ligand-gated ion channel; GluCl, glutamate-gated chloride channel; HEK293,
human embryonic kidney 293; LC-MS, gas-liquid chromatography coupled to mass spectrometry; OELa, essential oil extracts from Lippia alba;
PRED, predicted agonist-induced response; RDL, resistance-to-dieldrin channels; RUV, residual unexplained variance.
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and tropisetron are used in the clinic to alleviate nausea and
vomiting associated with chemotherapy, radiotherapy, and
general anesthesia. There has also been limited use of partial
agonists and competitive antagonists in the management
of irritable bowel syndrome (Moore et al., 2013). Allosteric
ligands include the anthelmintic ivermectin and general
anesthetic propofol, both of which bind to cavities in the
transmembrane domain of vertebrate, invertebrate, and
prokaryotic channels (Nury et al., 2011; Chiara et al., 2013;
Jayakar et al., 2013; Yip et al., 2013). Smaller terpenoids
such as menthol and thymol also bind in transmembrane
cavities, whereas more complex terpenoids such as bilobalide
and ginkgolide bind in the channel of the 5-HT3 receptor
and other Cys-loop receptors (Hawthorne et al., 2006;
Thompson et al., 2010; Lynagh and Lynch, 2012; Lynagh and
Laube, 2014).
Medicinal products containing terpenoids are widely avail-
able for the relief of gastrointestinal and respiratory disorders.
Although the pharmacological mechanisms of their active
ingredients are not well known, evidence suggests the actions
of some may result from effects at 5-HT3 receptors. For
example, menthol has an IC50 of 163 mM at 5-HT3 receptors
and blocks gut contractions at the same concentration
(Heimes et al., 2011; Ashoor et al., 2013). The ginger extracts
6-gingerol and 6-shogaol similarly inhibit 5-HT3 receptors and
5-HT–mediated gut contractions with micromolar potency
(Abdel-Aziz et al., 2006; Walstab et al., 2013, 2014). With an
increasing number of reports also describing the effects of
terpenoids at other receptors, the potential physiologic effects
of these compounds deserve investigation (Oz et al., 2015).
In this study, we investigate the pharmacology of the
terpenoids citral, linalool, and eucalyptol. We use nonlinear
mixed-effects modeling to determine their effects on the
electrophysiology of 5-HT3 receptors and, combined with flow
cytometry and in silico docking, investigate their modes of
action and potential binding sites. Using liquid chromatogra-
phy coupled to mass spectrometry (LC-MS), we also report the
terpenoid content of an essential oil extracted from Lippia
alba and determine its effects on the contraction of isolated
ileum and trachea.
Materials and Methods
Materials. Citral, eucalyptol, linalool (Fig. 1), and 5-hydroxytryptamine
were from Sigma-Aldrich (St. Louis, MO). Human 5-HT3A (accession
number: P46098) subunit cDNA was provided by J. Peters (Univer-
sity of Dundee, Dundee, UK). Essential oil of L. alba was purchased
and a species voucher was deposited on Prisco Bezerra Herbarium
(Federal University of Ceará, Ceará, Brazil) with the following
number identification: EAC-08474. Essential oil extracts from
L. alba (OELa)were analyzedbyLC-MSatParque deDesenvolvimento
Tecnológico (Ceara, Brazil).
Oocyte Maintenance. Oocytes from Xenopus laevis were pur-
chased from EcoCyte Bioscience (Castrop-Rauxel, Germany) and
stored at 16°C in ND96 (96 mM NaCl, 2 mM KCl, 1 mM MgCl2,
5 mM HEPES, pH 7.5).
Cell Culture. Human embryonic kidney 293 (HEK293) cells were
grown on 90-mm round tissue culture plates as monolayers in
Dulbecco’s modified Eagle’s medium (DMEM)/F12 (Gibco, Life Tech-
nologies, Carlsbad, CA) supplemented with 10% fetal bovine serum
(Sigma-Aldrich) at 37°C in a moist atmosphere containing 5% CO2.
Receptor Expression. 5-HT3A subunit cDNA was cloned into
pGEMHE for oocyte expression. cRNA was transcribed in vitro from a
linearized plasmid cDNA template using the mMessage mMachine
Ultra T7 Transcription kit (Ambion, Austin, TX). Stage V and VI
oocytes were injected with 50 nl of 100–500 ng ml21 cRNA (5–25 ng
injected), and currents were recorded 1–4 days postinjection.
5-HT3A subunit cDNA was cloned into pcDNA3.1 for expression in
HEK293 cells (ThermoFisher Scientific, Waltham, MA). Cells were
transiently transfected with this cDNA using polyethyleneimine
(25 kDa, linear, powder; Polysciences Inc., Eppelheim, Germany).
Thirtymicroliters of polyethyleneimine (1mgml21), 5mg of cDNA, and
1 ml of DMEM were incubated for 10 minutes at room temperature,
added dropwise to a 90-mm plate of 70–80% confluent HEK293 cells,
and incubated for 2–3 days before use.
Electrophysiology. Using two-electrode voltage clamp, Xenopus
oocytes were routinely clamped at260 mV using an OC-725 amplifier
(Warner Instruments, Hamden, CT), NI USB-6341 X Series DAQ
Device (National Instruments, Berkshire, UK), and the Strathclyde
Electrophysiology Software Package v4.7.3 (University of Strathclyde,
Glasgow, UK). Microelectrodes were fabricated from borosilicate glass
(GC120TF-10; Harvard Apparatus, Edenbridge, Kent, UK) using a
two-stage horizontal pull (P-97; Sutter Instrument Company, Novato,
CA) and filled with 3 M KCl. Pipette resistances ranged from 0.8 to
2.0 MV. Oocytes were placed in a perfusion chamber made from
2-mm-wide  30-mm-long silicon tubing that was cut in half length-
ways (total volume ∼0.1 ml), and were perfused with ND96 at a rate of
12 ml min21. Drug application was via a simple gravity-fed system
calibrated to run at the same rate. For inhibition measurements,
antagonists were routinely applied for 1 minute before coapplication
with 5-HT. A 3-minute wash was used between compound applica-
tions. Oils were dissolved in buffer containing 1% DMSO, freshly
prepared each day, and constantly stirred during the experiments.
Flow Cytometry. HEK293 cells expressing the 5-HT3 receptor
were grown in monolayers and harvested from a 90-mm culture dish
using 10 ml of Trypsin-EDTA (Sigma-Aldrich) for 10 minutes at 37°C.
Digestion was terminated by the addition of 25 ml DMEM1 10% fetal
bovine serum, and cells were pelleted at low speed for 2 minutes. The
pellet was resuspended in 3 ml of phosphate-buffered saline (137 mM
NaCl, 8.0 mMNa2HPO4, 2.7 mMKCl, 1.47 mMKH2PO4, pH 7.4), and
cells were filtered through a cell strainer (BD Falcon, Franklin Lakes,
NJ). Competition binding was measured by incubating HEK293 cells
with different concentrations of nonlabeled ligands and 10 nM
fluorescent granisetron (G-FL). After 10-minute incubation, cells were
pelleted and rapidly washed in phosphate-buffered saline before being
resuspended in the same buffer and analyzed on a BD Accuri C6 flow
cytometer (Becton, Dickinson and Company, Franklin Lakes, NJ) at
488-nm excitation/530-nm emission. The geometric mean was mea-
sured at each concentration of test compound and fitted to eq. 1 (see
Fig. 1. Chemical structures of diltiazem and the terpenoids used in this
study.
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the following section) using a least-squares method (GraphPad Prism
v4; GraphPad Software, La Jolla, CA).
Nonlinear Mixed-Effects Modeling. Inhibition of 5-HT–induced
currents was analyzed using Wings for NONMEM (distributed under a
GNU General Public License) and NONMEM 7.3.0 (Icon PLC, Dublin,
Ireland). NONMEM is typically used for population pharmacokinetic/
pharmacodynamic analyses and is ideally suited to simultaneouslymodel
fixed nonlinear effects (e.g., drug concentration-response relationships)
and random effects (e.g., variance in maximal peak current). Nonlinear
mixed-effects modeling of this sort cannot easily be done using more
familiar statistical packages. Specifically,NONMEMallows themodeling
of the relationship between drug and response, and importantly, the
random between-oocyte variance, which is considerable. NONMEM
enabled a single unified model to be created that included all electro-
physiological agonist and antagonist data. This comprised 532 individual
data points from 55 oocytes from the following experiments: 1) control
5-HT concentration-response data, 2) 5-HT concentration-response data
in the presence of test compounds, and 3) concentration-inhibition data at
fixed 5-HT (typically 1.7 mM) concentrations. The ability to allow for
between-oocyte variance enabled raw peak currents to be analyzed,
rather than normalized values. Normalization can obscure relationships
between parameters, resulting in inaccurate and imprecise estimates of
drug effects. Differences in peak currents and agonist potency between
different oocytes were modeled with population variances (v2) associated
with model parameters.
A structural model defined the relationship between the indepen-
dent variables (i.e., agonist and antagonist concentrations) and the
peak current (dependent variable). The agonist response wasmodeled
using the four-parameter logistic equation:
PRED5
Min02Max0
11

½A=102 pEC50;0
nHðAÞ1Max0 (1)
where PRED 5 predicted agonist-induced response, [A] 5 agonist
concentration;Min05PREDwhen [A]5 0;Max05PREDwhen [A]5‘;
pEC50,052log10[A] that induces PRED5 (Max01Min0)/2; and nH(A)5
agonist Hill coefficient. (In all cases, there was no basal current; hence,
Min0 was fixed to zero.)
Current responses can change during an experiment. If this effect is not
identified and quantified, it can distort estimates of agonist and compound
effects. The effect of time on the agonist response was modeled linearly as:
MaxT 5Max0ð11 ðT  nTÞÞ (2)
where Max05 as in eq. 1; MaxT5 PRED when [A]5 ‘ at time T; T5
time (hours) from start of individual experiment; and nT 5 change in
response per hour expressed as a proportion of the response at T 5
0 (nT 5 0 represents no change; nT 5 20.1 represents a reduction of
10%, and nT 5 0.1 represents an increase of 10% per hour).
The effect of the compounds on MaxT was modeled as follows:
MaxðDÞ5
MaxT
11

½D=102pIC50
nHðDÞ (3)
where MaxT5 PRED when [A]5 ‘ in the absence of drugD at time T
(eq. 2); Max(D)5 PREDwhen [A]5‘ in the presence of drugD at time
T; [D] 5 concentration of inhibitor drug; pIC50 5 2log10[D] in the
presence of which Max(D) 5 MaxT/2; and nH(D) 5 inhibitor Hill
coefficient. (This model assumes that, when [D] 5 ‘, PRED 5 0.)
The effect of the compounds on agonist pEC50 was modeled as follows:
pEC50ðDÞ5pEC50;02nGðDÞ
"
log10

½D102 pA2ðDÞ
nSðDÞ
11
#
(4)
where: pEC50,0 5 agonist pEC50 in the absence of drug D (eq. 1);
pEC50(D) 5 agonist pEC50 in the presence of drugD; [D]5 concentration
of drug; pA2(D) 5 pA2 of drug D; nS(D) 5 Schild coefficient for drug D;
and nG(D) 5 inhibition coefficient for drug D.
Variable Schild (nS) and inhibition (nG) coefficients enabled com-
pound effects other than competitive-like inhibition to be modeled,
and hypotheses about drug action on pEC50 to be statistically
evaluated using likelihood ratio tests. For example, when nS 5 1
and nG 5 1, the effect on agonist pEC50 is consistent with that of a
competitive antagonist, and when nG5 0, there is no effect of the drug
on agonist pEC50.
Random effects (h) were included, enabling parameter values from
different oocytes to differ from the typical, population parameter
estimates. The relationship between population and individual oocyte
parameters was modeled in the following two ways:
ParIND5ParPOP  ehi (5)
ParIND5ParPOP1hi (6)
where ParIND 5 individual parameter estimate; ParPOP 5 population
parameter estimate; and hi 5 h value representing the difference
between the population and an individual (i) parameter estimate.
Values of h from all oocytes (n 5 55) enabled a variance-covariance
(OMEGA) matrix for random effects to be constructed. This allows the
random variance inherent in different oocytes to be defined and
correlations in estimated parameters to be identified.
Residual unexplained variance (RUV) defines the difference be-
tween the observed and predicted values for a given set of conditions.
RUV was modeled as a function of PRED as follows:
RUV5a2  PREDg (7)
where RUV 5 residual unexplained variance between observed and
predicted current; PRED 5 predicted current; a2 5 variance param-
eter; and g 5 variance scaling parameter. When g 5 0, RUV is
constant irrespective of PRED and a 5 standard deviation of the
residual variability; when g 5 1, RUV is proportional to the response
(a2 5 RUV/PRED); when g 5 2, the coefficient of variation of the
residual variability is constant (a 5 SDRESID/PRED).
Maximum likelihood was used to identify best fit parameters for
specific models. A Laplacian method was used to obtain parameter
estimates. The objective function used by NONMEM is the extended
least squares. Parameter standard errors are from the covariance step
in NONMEM. Models were evaluated by examining both population-
and individual-weighted residuals and comparing Akaike and Bayes-
ian information criteria. Specific hypothesis tests are defined in
Table 1. They were performed by constraining parameters and
comparing resultant differences in extended least squares values
using likelihood ratio tests (Spalding and Jarvis, 2002; Mould and
Upton, 2013).
Drug Effects at 5-HT3AT6’S Receptors. The effects of the com-
pounds on 5-HT3AT6’S receptors were also evaluated. A total of 113 data
values from 11 oocytes comprising control 5-HT concentration-response
and compound concentration-inhibition curves were incorporated into
the wild-type receptor data set. Parameters were incorporated into the
model that defined changes in pEC50, pIC50,Max0, and pA2 values for
5-HT3AT6’S receptors. These parameters were statistically evaluated as
described earlier.
Dual Application. Dual application studies were performed as
previously described (Jarvis and Thompson, 2013). This is a simple
method to determine whether two channel blockers share the same
binding site (syntopic inhibition) or bind to separate locations (allotopic
inhibition). For each test compound, inhibition of a supramaximal
5-HT–induced (100 mM) response wasmeasured alone and in combination
with bilobalide (BB) and diltiazem (DTZ), both well characterized
5-HT3 blockers (Fig. 1; Thompson et al., 2011a). Concentrations of the
test compounds, BB and DTZ, were selected such that they caused
approximately 62% inhibition when used alone. From the results of
these experiments, predicted levels of inhibition were derived for both
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allotopic and syntopic modes of action. These predictions were
compared with data obtained experimentally using the same concen-
trations of the inhibitors acting together. For each oocyte, the change
in the amplitude of the 5-HT response over time was monitored and
taken into account. Inhibition by drugs was quantified in relation to
interpolated control responses for each time point.
The dual application measurements were compared statistically
with allotopic and syntopic predictions using a two-way analysis of
variance in which the oocyte was included as a random effect (SPSS
Statistics 20; IBM, Armonk, NY). Post-hoc testing was with Dunnett’s
method, comparing the measured data to each of the predictions.
Modeling and Ligand Docking. Using ClustalW (EMBL-EBI,
Cambridge, UK), the protein sequence of the human 5-HT3A subunit
(accession: P46098) was aligned with the sequence from the mouse
5-HT3A crystal structure (Protein Data Bank ID: 4PIR). Sequence
identity between mouse and human 5-HT3A was 89.1% (EMBOSS
Needle; EMBL-EBI; McWilliam et al., 2013) and alignments were
unambiguous. Five pentameric homology models were generated
using Modeler 9.13 (Andrej Sali, San Francisco, CA) with default
parameters, and the best model was selected using Ramachandran
plot analysis. Citral, eucalyptol, and linalool were constructed ab
initio in Chem3D Ultra 7.0 (CambridgeSoft, Cambridge, UK) and
energy minimized using the MM2 force field. Potential binding sites
were identified using a 20-Å docking sphere centered on the a-carbon
of L320, a residue located within the center of M2; therefore, within
each subunit, the docking sphere encompassed the full length of all
transmembrane a-helices. Docked poses were generated using the
GOLD docking program (version 3.0; Cambridge Crystallographic
Data Centre, Cambridge, UK) with the GOLDScore function and
default settings. For each compound, 10 docking poses were gener-
ated, and the poses and predicted hydrogen bonds were visualized
with PyMol v1.3 (Schrödinger, New York, NY).
Ileum Preparation. Guinea pig ileum was obtained from adult
male guinea pigs (200–300 g). The ileumwas cut into 1-cm lengths and
mounted longitudinally to a force transducer with a resting tension of
0.5 g in a 10-ml water-jacketed organ bath containing Krebs’ buffer
(118 mM NaCl, 4.7 mM KCl, 1.2 mMMgSO4, 1.25 mM CaCl2, 11 mM
glucose, 10mMHEPES, pH 7.2) continuously aeratedwith 95%O2/5%
CO2 and kept at 37°C. The ileum segmentswere allowed to equilibrate
for 10 minutes before the experiments were started, and contractile
responses were recorded using LabChart 6 (ADInstruments Ltd.,
Oxford, UK). 5-HT was applied to the serosal layer of the ileum, and
contractions were recorded for 10 seconds. Following drug applica-
tions, the organ bath was flushed twice with fresh Krebs’ solution, and
the ileum was allowed to recover for 10 minutes prior to the next
application. Antagonist was preapplied for 10minutes before coapplying
5-HT. Application of antagonists was not undertaken until two similar
(65%) 5-HT contractions were recorded in the absence of antagonist.
Experiments involving animals were approved by the University of
Cambridge Animal Welfare and Ethical Review Body (reference:
PHARM 004/15).
Tracheal Preparation. The trachea was removed from male
Wistar albino rats (250–350 g), cut into 2-cm lengths, and mounted
on a force transducer with a resting tension of 1.0 g in a 10-ml water-
jacketed organ bath containing modified Tyrode’s solution (136 mM
NaCl, 5 mM KCl, 0.98 mM MgCl2, 0.36 mM NaH2PO4, 2 mM CaCl2,
TABLE 1
Output from the best fit model describing the effects of 5-HT and inhibitors on the peak current
The best fit was selected based the stability of convergence on the objective function (extended least squares = 110.89) and a comparison of Akaike information criteria
(1,132.64) and Bayesian information criteria (1,226.72) values to alternative models. The model was further evaluated by examining the relationship between observed and
predicted values, and population and individual residuals.
Parameter Population ParameterEstimate
Population Variance
Model
Population
SD(v) or CORRb Hypothesis Tests
P Value
(LRT) Interpretation
Agonist (5-HT)
Min (mA) 0 (fixed) — — — —
Max (mA) 4.94 6 0.64  EXP(ɳ2) 0.95 6 0.10 H0: v2,2=0 No resulta Max varies between oocytes
COV(ɳ1,ɳ2) 0.87 6 0.05 H0: v1,2=0 4  1029 Max and pEC50 correlate strongly
pEC50 5.65 6 0.03 + ɳ1 0.18 6 0.02 H0: v1,1=0 4  10235 pEC50 varies between oocytes
nH 2.94 6 0.13 H0: nH(A)=3 0.64 Suggests three highly cooperative
agonist binding sites
nT 20.13 6 0.06 + ɳ7 0.19 6 0.06 H0: nT=0 0.052 Weak evidence for a change in
response with time
H0: v7=0 0.004 nT varies between oocytes
Citral
pIC50 3.92 6 0.05 + ɳ5 0.16 6 0.04 H0: v5=0 2  10211 pIC50 varies between oocytes
nH 1.34 6 0.08 H0: nH=1 5  1026 Indication of cooperative binding
nG 0 (fixed) H1: {nG,pA2,nS}0 0.94 No evidence that citral changes
agonist pEC50
Eucalyptol
pIC50 3.59 6 0.11 + ɳ4 0.32 6 0.07 H0: v4=0 1  10216 pIC50 varies between oocytes
nH 1.04 6 0.11 H0: nH=1 0.76 Suggests one inhibitor binding site
nG 1 (fixed) H0: nG=0 4  10215 Strong evidence that eucalyptol
changes agonist pEC50
pA2 3.09 6 0.09 + ɳ3 0.18 6 0.06 H0: v3=0 0.006 pA2 varies between oocytes
nS 1.70 6 0.24 H0: nS=1 0.001 Schild slope greater than that for
competitive antagonism
Linalool
pIC50 3.85 6 0.02 + ɳ6 0.05 6 0.02 H0: v6=0 0.023 pIC50 varies between oocytes
nH 2.19 6 0.26 H0: nH=2 0.46 Suggests two highly cooperative
inhibitor binding sites
nG 0 (fixed) H1: {nG,pA2,nS}0 0.11 No/weak evidence that linalool
changes agonist pEC50
RUV model
g 1.30 6 0.07 H0: g=0 1  10263 Residual error variance increases
with the current amplitude
a 0.30 6 0.01
COV, covariance; LRT, likelihood ratio test.
aNo stable convergence was obtained without a random effect included.
bParameter estimates are shown 6 standard errors.
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11.9 mMNaHCO3, 5.5 mM glucose, pH 7.4) continuously aerated with
95%O2/5%CO2 and kept at 37°C. Contractile responseswere recorded
using a force transducer (model FT03; Grass Technologies, Quincy,
MA) connected to a PC-based data acquisition system (Dataq, PM-
1000; DATAQ Instruments Inc., Akron, OH). The experiments were
conducted after an equilibration period of 60 minutes and three
successive similar contractile responses. Experiments were approved
by the local animal ethics committee (protocol number 00084/2014.2).
Results
Effects of Citral, Eucalyptol, and Linalool on 5-HT3
Receptor Currents. Neither 5-HT nor the terpenoid oils
(Fig. 1) had observable effects on uninjected Xenopus oocytes.
By contrast, application of 5-HT toXenopus oocytes expressing
5-HT3 receptors produced concentration-dependent, rapidly
activating, inward currents that slowly desensitized (Fig. 2A).
These responses were abolished by the 5-HT3 receptor–selective
antagonist granisetron (100 nM).
Citral, eucalyptol, and linalool inhibited 5-HT–evoked cur-
rents in oocytes expressing 5-HT3 receptors in a concentration-
dependent manner (Figs. 2 and 3) that was unaffected by the
clamp potential (Fig. 2G), but had no effect when applied
without 5-HT. Preapplication of the oils increased the level of
inhibition of the 5-HT response. Figure 2B shows how
simultaneous application of 5-HT and citral caused a small
reduction in the 5-HT peak current with subsequent responses
showing greater inhibition until a stable level of inhibition
was achieved. This is also seen in Fig. 2F, where a plot of
preapplication time against inhibition shows there was no
further increase in the level of inhibition after 30-second
preapplication for all three compounds.
Following removal of the compounds, full recovery of 5-HT
responses took approximately 3 minutes. This was indepen-
dent of the frequency of 5-HT application during the recovery
period, as shown for citral in Fig. 2C. The rate of recovery from
inhibitionwas similar whether the compoundswere applied in
the absence of (Fig. 2D, top), immediately prior to (Fig. 2D,
middle), or during (Fig. 2D, bottom) 5-HT application. The
slow recovery from inhibition was also seen when the three
compounds were added and removed in the continuous pres-
ence of 5-HT, as no rebound currents were seen, unlike the
more rapidly recovering channel blocker diltiazem (Fig. 2E).
These results show that citral, eucalyptol, and linalool
inhibit 5-HT3 receptors and defined the conditions for sub-
sequent experiments.
Quantification and Mechanism of Block. Studies at
varying 5-HT (0.3–300mM), citral (10, 30, 100, 200, 300, 500, 600,
and 1000 mM), eucalyptol (100, 200, 500, 660, and 2000 mM),
and linalool (100, 200, 500 mM) concentrations were carried
out at 260 mV with a 30-second preapplication of oils and
a 3-minute washout.
Peak current responses were reproducible within oocytes
but varied substantially between oocytes. A total of 532 peak
current values from 55 oocytes were analyzed using nonlinear
mixed-effects modeling to characterize and quantify the
effects of the compounds. Themodel included parameters that
defined concentration-dependent inhibitor effects on the
maximum response (Max0) and pEC50 of 5-HT.
The results from the best fit model are graphically repre-
sented in Fig. 3, with the parameter values shown in Table 1,
along with the outcome of hypothesis tests of these parameters.
Figure 4A shows a linear relationship between observed and
predicted peak current values. The most parsimonious and
stable variance-covariance model consisted of seven random
effects (Table 1). The analysis with NONMEM also revealed a
strong covariance between themaximum response (Max0) and
pEC50 of 5-HT (Fig. 4B: correlation 5 0.869 6 0.054), in-
dicating that oocytes with a higher peak current were more
sensitive to 5-HT. Failure to account for this covariance, such
as by normalizing data, misrepresents the variance in the
responses and could lead to inaccurate conclusions about the
effects of the inhibitors on 5-HT pEC50 values. For example,
the insets in Fig. 3 show normalized representations of the
same data revealing apparent shifts in the EC50 values for
citral and linalool that were not evident when the covariance
was taken into account. Furthermore, IC50 values derived
from these normalized data were lower (e.g., higher potency;
citral 5 98 mM; eucalyptol 5 174 mM; linalool 5 83 mM).
In the population of oocytes used (n 5 55), the 5-HT pEC50
was 5.65 6 0.03 (EC50 5 2.25 mM) with a Hill coefficient of
2.94 6 0.13 (Table 1). This is similar to previous findings and
is consistent with strong positive cooperativity between three
agonist binding sites (Thompson et al., 2011a; Thompson and
Lummis, 2013). Neither citral nor linalool altered the pEC50 of
5-HT, but both caused a concentration-dependent reduction in
themaximal peak current response (Fig. 3; Table 1). For citral,
the pIC50 was 3.92 6 0.05 (IC50 5 120 mM), and for linalool,
3.856 0.02 (IC505 141 mM). Eucalyptol also caused a reduction
in the maximal peak current with a pIC50 of 3.596 0.11 (IC505
258 mM), although this was accompanied by a reduction in the
pEC50 of 5-HT (Fig. 3; Table 1) with a pA2 and apparent Schild
coefficient (defining the shift in the agonist pEC50) of 3.096 0.09
and 1.70 6 0.24, respectively.
These results are consistent with a simple noncompetitive
mechanism of action for each compound, but suggest that
eucalyptol may have additional effects.
Effects on a 5-HT3AT6’S Receptor Mutant. Thymol and
carvacrol activate human 5-HT3 receptors from a transmem-
brane binding site (Lansdell et al., 2015). The compounds
studied here are structurally similar and could have weak
partial agonist activities that are difficult to detect at wild-
type receptors. The agonist sensitivity of the 5-HT3 receptor
can be enhanced by a T6’S substitution in the pore-lining M2
a-helix of the 5-HT3A subunit (Thompson and Lummis, 2013).
We therefore investigated the effects of 5-HT and the terpe-
noid oils in oocytes expressing the 5-HT3AT6’S mutant. A total
of 112 peak current responses from 11 different oocytes were
appended to the wild-type data set. These experiments
comprised control 5-HT concentration-response data and
concentration-inhibition data for 2 mM 5-HT. Parameters
were included in the model that allowed differences in agonist
and inhibitory effects to be quantified and evaluated.
There was no difference in the maximum 5-HT peak
current in the wild-type and 5-HT3AT6’S receptors [Max0(T6’S) /
Max0(WT) 5 0.98 6 0.30; P 5 0.93], but the mutant was more
sensitive to agonist as previously reported (Thompson and
Lummis, 2013). The 5-HT pEC50 was increased by 0.356 0.07.
Unlike the effects at wild-type receptors, eucalyptol did not
alter the 5-HT pEC50 [H0: nG(EUC/T6’S) 5 0; P 5 0.71). When
applied alone, citral, eucalyptol, and linalool did not evoke
currents in the 5-HT3AT6’S receptor mutant, but all abolished
5-HT–induced responses with inhibitory potencies that were
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reduced by approximately 2-fold when compared with their
effects at wild-type receptors (Table 2).
Competitive Binding with Granisetron. Our analysis
provides no evidence that citral or linalool competes with 5-HT
at the orthosteric site, whereas the effect of eucalyptol on 5-HT
pEC50 suggests that this ligand might. To further test for
orthosteric interactions, we measured the binding of a
fluorescent granisetron derivative (G-FL) together with the
three compounds using flow cytometry (Jack et al., 2015).
Both 5-HT and granisetron reduced G-FL binding in a
Fig. 2. Electrophysiological character-
ization of the actions of citral (Cit),
eucalyptol (Euc), and linalool (Lin) at
5-HT3 receptors. (A) Stable currents could
be evoked by 10 mM 5-HT applied at
1-minute intervals. (B) At 10 mM 5-HT,
stable levels of inhibition by citral, euca-
lyptol, or linalool were only seen following
preapplication but remained stable there-
after [also see (F)]. (C) Following inhibi-
tion, responses were slow to recover. For
all three compounds, full recovery was
achieved after 3 minutes and was in-
dependent of the frequency of 5-HT
activation during the recovery period.
(D) Receptors were inhibited in the closed
state as shown by the comparable levels
of inhibition seen when the compounds
were applied in the absence of 5-HT or
during 5-HT application. Inhibition per-
sisted after washout, and the recovery
time was unaltered by the timing or
frequency of subsequent 5-HT applica-
tions. (E) The slow washout of the
compounds is highlighted by the absence
of a rebound current following the re-
moval of citral, eucalyptol, or linalool. By
contrast, rebound was clearly seen fol-
lowing the removal of diltiazem, a chan-
nel blocker with faster recovery from
inhibition. (F) At a concentration of 300 mM,
the oils required 30-second preapplica-
tion to stably inhibit the 10 mM 5-HT
response. At lower concentrations, the
effect of preapplication was less apparent,
since the 5-HT response took longer to
reach a stable peak current. (G) The level
of inhibition at +40 mV or 260 mV was
the same for all three compounds.
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concentration-dependent manner (Fig. 5A). Binding of G-FL
was unaffected by citral, eucalyptol, or linalool at concentra-
tions up to 1 mM (Fig. 5B).
Dual Application of Citral, Eucalyptol, or Linalool in
the Presence of Bilobalide or Diltiazem. We have pre-
viously shown that simultaneous application of two drugs can
be used to probe the sites of action of channel blockers (Jarvis
and Thompson, 2013). Here, we applied each of the oils in the
presence of bilobalide or diltiazem, channel-blocking antago-
nists that bind at the 2’-6’ and 7’ regions of the 5-HT3 receptor
pore, respectively (Thompson et al., 2011a).
For citral (Fig. 6A), measured dual inhibition was no
different from the allotopic predictions for bilobalide (P 5
0.95) or diltiazem (P5 0.42), but was greater than the syntopic
predictions (BB, P 5 0.031; DTZ, P 5 0.0004). For eucalyptol
(Fig. 6B), dual inhibition was similar to the allotopic
Fig. 2. Continued
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prediction for bilobalide (P 5 0.38) but greater than the
allotopic prediction for diltiazem (P 5 0.013). For linalool
(Fig. 6C), dual inhibition was greater than the allotopic
prediction for both bilobalide (P 5 0.02) and diltiazem (P 5
0.06).
These results suggest that citral, eucalyptol, and linalool do
not share binding sites with the channel blockers bilobalide or
diltiazem, but may enhance their effects.
Transmembrane Binding Sites. Given the lipophilicity
of the oils and their noncompetitive mechanism of action, we
sought to identify potential binding sites in the transmem-
brane domain using in silico ligand docking in a homology
model of the human 5-HT3 receptor. Using a loosely defined
binding site radius of 20 Å that encompassed the whole of the
transmembrane domain, themajor binding cavity for all of the
ligands was predicted to be at the interface of two adjacent
subunits, betweenM1-M2 of the principal subunit andM2-M3
of the complementary subunit. For linalool, all 10 docked
poses were similarly orientated at the intersubunit interface
within only a 2.29-Å root-mean-square deviation (Fig. 7A).
Eucalyptol docked at two locations, both of which were
clustered at the same site between two adjacent subunits
(Fig. 7B). For citral, two sites were predicted, with the major
docked pose cluster (6/10) at the same intersubunit cavity, and
a minor site (4/10) at the lipid-exposed intracellular interface
of the M1 and M4 a-helices (Fig. 7C). Linalool was the only
compound predicted to make hydrogen bond contacts with the
protein (in 4/10 docked poses), which were between the
hydroxyl of linalool and the backbone carbonyl of Thr6’ in
M2 (Fig. 7D).
These results suggest that all three compounds could bind to
a transmembrane cavity located at the interface of adjacent
subunits.
Physiologic Effects. L. alba is used medicinally through-
out Central and South America as a means of alleviating
gastrointestinal discomfort and for respiratory ailments
(Hennebelle et al., 2008). Here, we analyzed an OELa by
LC-MS and detected that the main compounds were the terpe-
noids citral (75.9%; 41.8% geranial 1 34.1% neral), 1-limoneno
(9.8%), carvone (8.9%), gamma-terpinene (2.0%), and benzene
[1-methyl-3-(1-methylethyl; 1.0%].
To determine whether the properties of this essential oil
could be physiologically relevant, we measured its effects on
5-HT3 receptors expressed in oocytes and on smooth muscle
contractions in rat trachea and guinea pig ileum. At 5-HT3
receptors expressed in oocytes, OELa had no effect when
applied alone, but fully and reversibly inhibited the 2 mM
5-HT response with an IC50 of 45 mg ml
21 (n 5 5; Fig. 8A). In
rat trachea, 5-HT-induced contractions were concentration-
dependent and substantially inhibited by 10 mM of the 5-HT3
receptor antagonist granisetron (Fig. 8B). OELa also abol-
ished contractions induced by 10 mM 5-HT with an IC50 of
200 mgml21 (Fig. 8C). 5-HT–evoked contractions of guinea pig
ileum were also inhibited by granisetron, and OELa had an
IC50 of 20 mg ml
21 (n 5 6; Fig. 8D). In both rat trachea and
Fig. 3. Inhibition of the 5-HT3 receptor by citral, eucalyptol, or linalool.
5-HT–induced currents were measured at 260 mV in the absence or
presence of various concentrations of citral (A), eucalyptol (B), or linalool
(C) following a 30-second preapplication. The data were analyzed as
described in the text, and the output of this nonlinear mixed-effects
modeling is shown in Table 1. The main features of the structural model
are illustrated here. The dotted lines show the effect of the compounds on
the EC50. The insets show normalized data at the same inhibitor
concentrations; for citral and linalool, the apparent shifts in the EC50 seen
in this normalized data are artifacts caused by the normalization.
Additional data at 10, 30, 300, 600, and 1000 mM citral and 200 and 660 mM
eucalyptol were also collected, but the curves are omitted for clarity.
556 Jarvis et al.
 at A
SPET Journals on D
ecem
ber 14, 2016
jpet.aspetjournals.org
D
ow
nloaded from
 
guinea pig ileum, recovery of contractions required extended
washes, particularly at higher concentrations (Fig. 8E).
These results show that that OELa has a high citral content
and inhibits 5-HT3 receptors expressed in Xenopus oocytes
and 5-HT–induced smooth muscle contraction in the tra-
chea and ileum.
Discussion
This study describes the inhibitory effects of citral, euca-
lyptol, and linalool on human 5-HT3 receptors. These terpe-
noids can be added to a growing list of structurally related
compounds that modulate a wide range of voltage- and ligand-
gated ion channels, including 5-HT3 receptors and their
related vertebrate, invertebrate, and prokaryotic homologs
(Hales and Lambert, 1991; Barann et al., 2000; Hall et al.,
2004; Garcia et al., 2006; Ashoor et al., 2013; Walstab et al.,
2014; Lansdell et al., 2015; Ziemba et al., 2015).
All of the essential oils inhibited 5-HT–mediated currents
with IC50 values in the micromolar range. Non-competitive
antagonism was shown by them causing a concentration-
dependent reduction in themaximal 5-HT response and by not
competing with the fluorescent antagonist G-FL. The Hill
coefficients for the reduction in the 5-HT response suggested
that there may be multiple binding sites with strong cooper-
ativity for linalool (nH 5 2.2), weak cooperativity for citral
(nH 5 1.3), and no cooperativity for eucalyptol (nH 5 1.0).
There was evidence that, at higher concentrations, eucalyptol
also caused a rightward shift in the EC50 of 5-HT (pA25 3.09),
indicating an additional inhibitory mechanism. A competitive
mechanism is conceivable, although not compelling, given
that the shift had a Schild coefficient of 1.7 and that eucalyptol
failed to compete with G-FL. However, given the different
binding orientations of 5-HT and granisetron in cocrystal
structures, it is possible that an inhibitor could compete with
one of these ligands but not the other (Colquhoun, 2007;
Kesters et al., 2013). At the T6’S mutants, there was no
evidence of a eucalyptol-induced change in agonist EC50. This
is probably because this effect occurs at higher concentrations
(pA2 5 3.09) than the reduction in maximal current (pIC50 5
3.59), and the overall potency of the terpenoids was reduced at
these mutants.
Mixed-effects modeling also revealed a strong correlation
between the maximal peak current and pEC50 (Fig. 5B). Since
receptor expression is difficult to control, many investigators
normalize data to facilitate comparisons between experi-
ments. However, if the implicit assumption that agonist
response is independent of expression levels is not justified,
then data normalization may lead to inaccurate and mis-
leading conclusions. In the current study, a particular advan-
tage of the nonlinear mixed-effects modeling was that variant
maximal current responses could be modeled as a random
effect, thereby generating more accurate quantitative conclu-
sions (normalization yielded higher IC50 values, suggesting
that this method of analysis overestimated the potency of the
compounds) and revealing unexpected biologic phenomena
(such as the covariance of the EC50 and Max0). This modeling
approachwas also able to identify pleiotropic drug effects (e.g.,
eucalyptol), for which the properties of the compoundswe used
were particularly well suited. Therefore, the data we present
clearly highlight the superior value of nonlinear mixed-effects
modeling, revealing phenomena that would otherwise have
been missed using the standard procedure of normalizing
data. Nonlinear mixed-effects modeling is often used for
pharmacokinetic-pharmacodynamic data analysis, but has
broad applicability in other quantitative pharmacological
studies (Mould and Upton, 2013). For example, by modeling
Fig. 4. Nonlinear mixed-effects modeling. (A) The relationship between
observed and predicted peak current values for the best fit model
described in Table 1 (n = 532). The values cluster around the line of unity
with no apparent systematic deviation, showing that data are well fitted
by the model. (B) Modeled Max0 and pEC50,0 parameter values for
individual oocytes (n = 55 oocytes). The clear and strong relationship
between these parameter estimates (correlation = 0.8696 0.054) suggests
that oocytes with a high maximum peak current are more sensitive to
5-HT. This relationship is obscured by data normalization.
TABLE 2
Effect of a T6’S mutation on inhibitor pIC50 values
Agonist DpEC50 P (H0: DpEC50=0) pEC50
a
5-HT 0.35 6 0.07 3  1026 6.00 6 0.08
Inhibitorb
Citral 20.36 6 0.10 0.002 3.55 6 0.11
Eucalyptol 20.45 6 0.22 0.046 3.14 6 0.05
Linalool 20.34 6 0.04 5  1027 3.51 6 0.24
aStandard errors were calculated from the errors of the pEC50/pIC50 and DpEC50/
DpIC50 values using propagation of error calculations.
bThere was no significant difference between the DpIC50 values for the three
inhibitors (P = 0.87).
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all data simultaneously (e.g., by incorporating both agonist
concentration-activation and antagonist concentration-
inhibition data), it generates a more comprehensive model
of drug action and a statistically more powerful framework
within which to evaluate specific hypotheses. This is
particularly valuable when it is important to minimize use of
resources, such as experimental animals or scarce test
compounds.
Previously, we used a dual-applicationmethod to determine
whether channel blockers have overlapping or independent
binding sites within the 5-HT3 receptor pore (Thompson et al.,
2011b; Jarvis and Thompson, 2013). Results suggesting that
bilobalide, ginkgolide B, and picrotoxinin shared binding sites
and that diltiazem bound elsewhere were later confirmed by
mutating channel-lining residues (Thompson et al., 2011a).
Dual application of citral with bilobalide or diltiazem caused
inhibition consistent with the allotopic model, indicating that
citral binds at distinct sites to these two channel blockers.
Eucalyptol and linalool caused dual inhibition at levels
significantly greater than the syntopic predictions, indicating
that these compounds also bind to distinct sites. However,
dual inhibition exceeded the allotopic prediction, suggest-
ing that eucalyptol and linalool may allosterically modulate
binding of bilobalide and diltiazem. Alternatively, as the
allotopic model assumes that the inhibitors do not modify
the action of the agonist, it is possible that a reduced
sensitivity to 5-HT could contribute to this effect, a possibility
that is supported by the rightward shift in the 5-HT EC50
caused by eucalyptol.
The lipophilic nature of the oils suggests that the binding
sites of citral, eucalyptol, and linalool are located in the
transmembrane region, consistent with the slow wash-in
and washout that is observed when compounds must first
diffuse into membranes before reaching their target (Turina
et al., 2006). This hypothesis is supported by our electrophys-
iology and flow cytometry data, which indicate a noncompet-
itive mechanism of action, and by the nonoverlapping binding
sites predicted by our dual-application experiments. To probe
for potential binding sites, we used homology modeling and
docking, which predicted that all three oils share a common
binding site located in a cavity between the transmembrane
a-helices of adjacent subunits. The terpenoids carvacrol and
thymol have been proposed to bind in a similar cavity within
the 5-HT3 receptor, and this location is also conserved among
other Cys-loop receptors (Lansdell et al., 2015). Crystal
structures of the invertebrate Cys-loop receptor glutamate-
gated chloride channel reveal an equivalent intersubunit
cavity occupied by ivermectin, and residues at this location
are implicated in ivermectin binding at GABAA and glycine
receptors (Lynagh and Lynch, 2012). A similar binding site
has been identified for propofol at a prokaryotic homolog
(Gloeobacter violaceus ligand-gated ion channel) and other
eukaryotic Cys-loop receptors (Nury et al., 2011; Jayakar
et al., 2013; Yip et al., 2013; Lynagh and Laube, 2014). The
similar activities of these compounds across the Cys-loop
receptor family suggest that this region is widely conserved
and could be an amenable target for novel allosteric modu-
lators (Corradi et al., 2011; Howard et al., 2011; Trattnig
et al., 2012). To date, 5-HT3 receptor antagonists have
been typically used to prevent nausea and vomiting, but
the association of these receptors with other disorders,
such as irritable bowel syndrome, anxiety, and diabetic
neuropathy, suggests that there may be scope for other
therapeutic applications (Walstab et al., 2010; Silva et al.,
2015).
The structurally related compounds carvacrol and thymol
are also partial agonists at the 5-HT3 receptor (Lansdell et al.,
2015; Ziemba et al., 2015). As low-efficacy partial agonism
can sometimes be overlooked and mistaken as antagonism
[e.g., the 5-HT3 ligand quipazine (Thompson and Lummis,
2013)], we tested citral, eucalyptol, and linalool for agonist
activity using a 5-HT3 receptor mutant with enhanced
agonist sensitivity. Substitution of the 5-HT3A subunit
channel-lining 6’ Thr with the equivalent 6’ Ser from the
5-HT3B subunit creates a hypersensitive mutant with in-
creased sensitivity to a range of 5-HT3 agonists (Thompson
and Lummis, 2013). Consistent with previous reports, our
results reveal a 2-fold increase in 5-HT sensitivity in the
T6’Smutant. However—with citral, eucalyptol, and linalool—
no agonist action, or potentiation of the 5-HT response, was
observed at the mutant receptor, confirming that they are
antagonists. In silico docking predicted that the 6’ Thr
residue may establish a hydrogen-bond interaction with
linalool, although the interaction was with the backbone
carbonyl and therefore unlikely to be greatly affected by
amino acid substitution. Indeed, a 2-fold reduction in the
potency of all the inhibitors at 5-HT3AT6’S mutants suggests
a nonspecific effect rather than a modification of hydrogen-
bond interactions for linalool alone.
Fig. 5. Competition of a fluorescent 5-HT3 receptor competitive antago-
nist. (A) Competition of 10 nMG-FL with the agonist 5-HT (pIC50 = 6.106
0.03, nH = 2.1, IC50 = 0.79 mM, n = 4) and the competitive antagonist
granisetron (pIC50 = 8.42 6 0.03, nH = 1.1, IC50 = 3.8 nM, n = 6). (B) The
test compounds citral (n = 3), eucalyptol (n = 3), and linalool (n = 3) show no
competition with G-FL.
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Fig. 6. Inhibition of the 5-HT3 receptor using a dual-application approach. 5-HT3 receptors were activated with a supramaximal (100 mM) concentration
of 5-HT. Concentrations of BB, DTZ, and the terpenoids were preselected to inhibit the response by approximately 62% when used alone. Results are
shown in the white bars. These same concentrations were then applied in dual combinations, giving results shown in the black bars. The gray bars are
the allotopic (allo) and syntopic (syn) predictions based on the levels of inhibition caused by the compounds alone. Data are the mean6 S.E.M. Two-way
analysis of variance with Dunnett’s post-hoc test was used (IBM SPSS Statistics 20) to compare actual and predicted dual application responses. (A)
Citral (n = 7). For BB, P = 0.019 (analysis of variance), P = 0.95 (H0: BB+citral = allo), P = 0.031 (H0: BB+citral = syn); and for DTZ, P = 0.0005 (analysis
of variance), P = 0.42 (H0: DTZ+citral = allo), P = 0.0004 (H0: DTZ+citral = syn). (B) Eucalyptol (n = 6). For BB, P = 0.015 (analysis of variance), P = 0.38
(H0: BB+eucalyptol = allo), P = 0.009 (H0: BB+eucalyptol = syn); and for DTZ, P = 0.00008 (analysis of variance), P = 0.013 (H0: DTZ+eucalyptol = allo),
P = 0.00004 (H0: DTZ+eucalyptol = syn). (C) Linalool (n = 5). For BB, P = 0.0006 (analysis of variance), P = 0.023 (H0: BB+linalool = allo), P = 0.0004
(H0: BB+linalool = syn); and for DTZ, P = 0.003 (analysis of variance), P = 0.056 (H0: DTZ+linalool = allo), P = 0.002 (H0: DTZ+linalool = syn). In all
experiments, stable levels of inhibition were achieved by applying the compounds for 1 minute before 5-HT was added.
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Several plant extracts are commonly used to treat gastro-
intestinal discomfort and respiratory disorders, and their
components, such as citral and menthol, are reported to have
relaxant effects on gut smooth muscle (Tangpu and Yadav,
2006; Hennebelle et al., 2008, Devi et al., 2011; Walstab et al.,
2014). Here, we show that OELa, an extract from L. alba,
inhibits 5-HT3 receptors expressed in oocytes (IC505 45mgml
21)
and 5-HT–evoked contractions in both rat trachea (IC50 5
200 mg ml21) and guinea pig ileum (IC50 5 20 mg ml
21). Using
LC-MS, we found the principal component of this oil was citral
(75.9%), which could account for these effects; the IC50 of
OELa at expressed receptors is 45 mg ml21, which con-
tains ∼220 mM citral and is close to the IC50 of citral alone
(120 mM). It has been reported that 5-HT–mediated smooth
muscle contractions in the trachea and ileum are partially
regulated by 5-HT2, 5-HT3, and 5-HT4 receptors. Our results
with the antagonist granisetron confirm a role for 5-HT3
receptors, similar to previous reports that used 5-HT3 receptor
antagonists to inhibit 5-HT–mediated smooth muscle contrac-
tions (Rocha eSilva et al., 1953;Tuladhar et al., 1997;Fernandez-
Rodriguez et al., 2010; Kelley et al., 2014). Our results may
therefore provide a mechanism for the medicinal use of these
oils for relieving gastrointestinal and respiratory ailments.
The IC50 values we report here are comparable to those for
similar terpenoid compounds, such as menthol (163 mM),
and it has been suggested that oral administration of this
compound could reach an equivalent concentration in vivo
(Ashoor et al., 2013). However, to achieve this concentration in
rat brain, the required intraperitoneal dose of menthol was
100 mg/kg, considerably higher than doses used for human
medicinal products (Pan et al., 2012). Therefore, in humans, it
is unlikely that systemic administration of typical doses would
result in concentrations that are active at 5-HT3 receptors,
although it is possible that higher local concentrations
following topical administration (e.g., in airway, skin, or gut)
could reach pharmacologically active levels (Falk-Filipsson
et al., 1993). For most terpenoids, including linalool and
eucalyptol, blood and tissue concentrations have not been
reported, but toxicological studies suggest that many are well
tolerated (Oz et al., 2015). This suggests that there is still
scope for therapeutic applications, with syntheticmodification
possibly providing a means for improving their potency and
receptor selectivity.
In summary, we used nonlinear mixed-effects modeling to
show that the oils citral, eucalyptol, and linalool inhibit
homomeric 5-HT3 receptors via noncompetitive mechanisms.
Both electrophysiology and flow cytometry point to binding
locations that do not overlap with the orthosteric binding site,
whereas our dual-application experiments suggest actions
that are mediated from outside the pore. Docking predicts a
transmembrane binding site located between the a-helices of
adjacent subunits, and is supported by the binding of related
compounds to similar allosteric sites identified in both 5-HT3
and other members of this ligand-gated ion channel family.
These results demonstrate the value of analyzing data using
nonlinear mixed-effects modeling and further highlight a
conserved transmembrane binding site as a potential target
for the development of novel allosteric ligands.
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Fig. 8. The effects of OELa. (A) Concentration inhibition of 2 mM5-HT–induced currents by OELa inXenopus oocytes expressing the 5-HT3 receptor (n =
5). (B) Rat tracheal contraction in response to 5-HT in the absence (., n = 6) and following a 10-minute preapplication with 10 mM granisetron (,, n = 3).
(C) Concentration-inhibition of the 10 mM 5-HT–evoked tracheal contractile response by OELa (n = 4). (D) Inhibition by OELa of 10 mM 5-HT–evoked
guinea pig ileum contractions (n = 6). (E). Example recordings from 5-HT–evoked (black bars) contractions of guinea pig ileum and their inhibition by 30,
60, and 100 mg ml21 OELa. At concentrations $60 mg ml21 OELa, the 5-HT–evoked contractions became increasingly slow to recover. Following a
control 5-HT response (0.6 mM, black bar), the addition of 100 mg ml21 OELa continued to inhibit the 5-HT–evoked contractions 50 minutes later,
although an acetylcholine (1 mM, gray bar) response was unaltered. Parameters defining the curves are shown in the text.
Essential Oils That Inhibit 5-HT3 Receptors 561
 at A
SPET Journals on D
ecem
ber 14, 2016
jpet.aspetjournals.org
D
ow
nloaded from
 
Switzerland) for reviewing the chemical structures and providing
G-FL, and Ruth Murrell-Lagnado for hosting the experimental work.
Authorship Contributions
Participated in research design: Thompson.
Conducted experiments: Thompson, Barbosa.
Contributed new reagents or analytic tools: Barbosa, Jarvis.
Performed data analysis: Thompson, Jarvis.
Wrote or contributed to the writing of the manuscript: Thompson,
Jarvis.
References
Abdel-Aziz H, Windeck T, Ploch M, and Verspohl EJ (2006) Mode of action of gin-
gerols and shogaols on 5-HT3 receptors: binding studies, cation uptake by the
receptor channel and contraction of isolated guinea-pig ileum. Eur J Pharmacol
530:136–143.
Ashoor A, Nordman JC, Veltri D, Yang KH, Shuba Y, Al Kury L, Sadek B, Howarth
FC, Shehu A, and Kabbani N, et al. (2013) Menthol inhibits 5-HT3 receptor-
mediated currents. J Pharmacol Exp Ther 347:398–409.
Barann M, Dilger JP, Bönisch H, Göthert M, Dybek A, and Urban BW (2000) In-
hibition of 5-HT3 receptors by propofol: equilibrium and kinetic measurements.
Neuropharmacology 39:1064–1074.
Caputi L and Aprea E (2011) Use of terpenoids as natural flavouring compounds in
food industry. Recent Pat Food Nutr Agric 3:9–16.
Chiara DC, Jayakar SS, Zhou X, Zhang X, Savechenkov PY, Bruzik KS, Miller KW,
and Cohen JB (2013) Specificity of intersubunit general anesthetic-binding sites in
the transmembrane domain of the human a1b3g2 g-aminobutyric acid type A
(GABAA) receptor. J Biol Chem 288:19343–19357.
Colquhoun D (2007) Why the Schild method is better than Schild realised. Trends
Pharmacol Sci 28:608–614.
Corradi J, Andersen N, and Bouzat C (2011) A novel mechanism of modulation of
5-HT₃A receptors by hydrocortisone. Biophys J 100:42–51.
Devi RC, Sim SM, and Ismail R (2011) Spasmolytic effect of citral and extracts of
Cymbopogon citratus on isolated rabbit ileum. J Smooth Muscle Res 47:
143–156.
Falk-Filipsson A, Löf A, Hagberg M, Hjelm EW, and Wang Z (1993) d-limonene
exposure to humans by inhalation: uptake, distribution, elimination, and effects on
the pulmonary function. J Toxicol Environ Health 38:77–88.
Fernandez-Rodriguez S, Broadley KJ, Ford WR, and Kidd EJ (2010) Increased
muscarinic receptor activity of airway smooth muscle isolated from a mouse model
of allergic asthma. Pulm Pharmacol Ther 23:300–307.
García DA, Bujons J, Vale C, and Suñol C (2006) Allosteric positive interaction of
thymol with the GABAA receptor in primary cultures of mouse cortical neurons.
Neuropharmacology 50:25–35.
Hales TG and Lambert JJ (1991) The actions of propofol on inhibitory amino acid
receptors of bovine adrenomedullary chromaffin cells and rodent central neurones.
Br J Pharmacol 104:619–628.
Hall AC, Turcotte CM, Betts BA, Yeung WY, Agyeman AS, and Burk LA (2004)
Modulation of human GABAA and glycine receptor currents by menthol and re-
lated monoterpenoids. Eur J Pharmacol 506:9–16.
Hassaine G, Deluz C, Grasso L, Wyss R, Tol MB, Hovius R, Graff A, Stahlberg H,
Tomizaki T, Desmyter A, Moreau C, Li XD, Poitevin F, Vogel H, and Nury H (2014)
X-ray structure of the mouse serotonin 5-HT3 receptor. Nature 512:276–281.
Hawthorne R, Cromer BA, Ng HL, Parker MW, and Lynch JW (2006) Molecular
determinants of ginkgolide binding in the glycine receptor pore. J Neurochem 98:
395–407.
Heimes K, Hauk F, and Verspohl EJ (2011) Mode of action of peppermint oil and
(-)-menthol with respect to 5-HT3 receptor subtypes: binding studies, cation uptake
by receptor channels and contraction of isolated rat ileum. Phytother Res 25:
702–708.
Hennebelle T, Sahpaz S, Joseph H, and Bailleul F (2008) Ethnopharmacology of
Lippia alba. J Ethnopharmacol 116:211–222.
Howard RJ, Murail S, Ondricek KE, Corringer PJ, Lindahl E, Trudell JR, and Harris
RA (2011) Structural basis for alcohol modulation of a pentameric ligand-gated ion
channel. Proc Natl Acad Sci USA 108:12149–12154.
Sali A and Blundell TL (1993) Comparative protein modelling by satisfaction of
spatial restraints. J Mol Biol 234:779–815.
Jack T, Simonin J, Ruepp MD, Thompson AJ, Gertsch J, and Lochner M (2015)
Characterizing new fluorescent tools for studying 5-HT₃ receptor pharmacology.
Neuropharmacology 90:63–73.
Jarvis GE and Thompson AJ (2013) A golden approach to ion channel inhibition.
Trends Pharmacol Sci 34:481–488.
Jayakar SS, Dailey WP, Eckenhoff RG, and Cohen JB (2013) Identification of pro-
pofol binding sites in a nicotinic acetylcholine receptor with a photoreactive pro-
pofol analog. J Biol Chem 288:6178–6189.
Kelley SP, Walsh J, Kelly MC, Muhdar S, Adel-Aziz M, Barrett ID, and Wildman SS
(2014) Inhibition of native 5-HT3 receptor-evoked contractions in guinea pig and
mouse ileum by antimalarial drugs. Eur J Pharmacol 738:186–191.
Kessler A, Sahin-Nadeem H, Lummis SC, Weigel I, Pischetsrieder M, Buettner A,
and Villmann C (2014) GABA(A) receptor modulation by terpenoids from Sideritis
extracts. Mol Nutr Food Res 58:851–862.
Kesters D, Thompson AJ, Brams M, van Elk R, Spurny R, Geitmann M, Villalgordo JM,
Guskov A, Danielson UH, and Lummis SC, et al. (2013) Structural basis of ligand
recognition in 5-HT3 receptors. EMBO Rep 14:49–56.
Lansdell SJ, Sathyaprakash C, Doward A, and Millar NS (2015) Activation of human
5-hydroxytryptamine type 3 receptors via an allosteric transmembrane site. Mol
Pharmacol 87:87–95.
Lynagh T and Laube B (2014) Opposing effects of the anesthetic propofol at pen-
tameric ligand-gated ion channels mediated by a common site. J Neurosci 34:
2155–2159.
Lynagh T and Lynch JW (2012) Ivermectin binding sites in human and invertebrate
Cys-loop receptors. Trends Pharmacol Sci 33:432–441.
McWilliam H, Li W, Uludag M, Squizzato S, Park YM, Buso N, Cowley AP, and Lopez
R (2013) Analysis Tool Web Services from the EMBL-EBI. Nucleic Acids Res 41:
W597–W600.
Moore NA, Sargent BJ, Manning DD, and Guzzo PR (2013) Partial agonism of 5-HT3
receptors: a novel approach to the symptomatic treatment of IBS-D. ACS Chem
Neurosci 4:43–47.
Mould DR and Upton RN (2013) Basic concepts in population modeling, simulation,
and model-based drug development-part 2: introduction to pharmacokinetic mod-
eling methods. CPT Pharmacometrics Syst Pharmacol 2:e38.
Nury H, Van Renterghem C, Weng Y, Tran A, Baaden M, Dufresne V, Changeux JP,
Sonner JM, Delarue M, and Corringer PJ (2011) X-ray structures of general an-
aesthetics bound to a pentameric ligand-gated ion channel. Nature 469:428–431.
Oz M, Lozon Y, Sultan A, Yang KH, and Galadari S (2015) Effects of monoterpenes on
ion channels of excitable cells. Pharmacol Ther 152:83–97.
Pan R, Tian Y, Gao R, Li H, Zhao X, Barrett JE, and Hu H (2012) Central mecha-
nisms of menthol-induced analgesia. J Pharmacol Exp Ther 343:661–672.
Rocha e Silva M, Valle JR, and Picarelli P (1953) A pharmacological analysis of the
mode of action of serotonin (5-hydroxytryptamine) upon the guinea-pig ileum.
Br Pharmacol Chemother 8:378–388.
Silva M, Martins D, Tavares I, and Morgado C (2015) Inhibition of spinal 5-HT3R
reverted diabetes-induced mechanical hypersensitivity in a GABAAR-mediated
neurotransmission-dependent manner. Neuroscience 304:228–239.
Spalding MD and Jarvis GE (2002) The impact of the 1998 coral mortality on reef fish
communities in the Seychelles. Mar Pollut Bull 44:309–321.
Tangpu V and Yadav AK (2006) Antidiarrhoeal activity of Cymbopogon citratus and
its main constituent, citral. Pharmacologyonline 2:290–298.
Thompson AJ, Duke RK, and Lummis SC (2011a) Binding sites for bilobalide, dil-
tiazem, ginkgolide, and picrotoxinin at the 5-HT3 receptor. Mol Pharmacol 80:
183–190.
Thompson AJ, Jarvis GE, Duke RK, Johnston GA, and Lummis SC (2011b)
Ginkgolide B and bilobalide block the pore of the 5-HT₃receptor at a location that
overlaps the picrotoxin binding site. Neuropharmacology 60:488–495.
Thompson AJ, Lester HA, and Lummis SC (2010) The structural basis of function in
Cys-loop receptors. Q Rev Biophys 43:449–499.
Thompson AJ and Lummis SC (2013) A single channel mutation alters agonist ef-
ficacy at 5-HT3A and 5-HT3AB receptors. Br J Pharmacol 170:391–402.
Trattnig SM, Harpsøe K, Thygesen SB, Rahr LM, Ahring PK, Balle T, and Jensen AA
(2012) Discovery of a novel allosteric modulator of 5-HT3 receptors: inhibition and
potentiation of Cys-loop receptor signaling through a conserved transmembrane
intersubunit site. J Biol Chem 287:25241–25254.
Tuladhar BR, Kaisar M, and Naylor RJ (1997) Evidence for a 5-HT3 receptor in-
volvement in the facilitation of peristalsis on mucosal application of 5-HT in the
guinea pig isolated ileum. Br J Pharmacol 122:1174–1178.
Turina AV, Nolan MV, Zygadlo JA, and Perillo MA (2006) Natural terpenes: self-
assembly and membrane partitioning. Biophys Chem 122:101–113.
Walstab J, Krüger D, Stark T, Hofmann T, Demir IE, Ceyhan GO, Feistel B, SchemannM,
and Niesler B (2013) Ginger and its pungent constituents non-competitively inhibit
activation of human recombinant and native 5-HT3 receptors of enteric neurons.
Neurogastroenterol Motil 25:439–447, e302.
Walstab J, Rappold G, and Niesler B (2010) 5-HT(3) receptors: role in disease and
target of drugs. Pharmacol Ther 128:146–169.
Walstab J, Wohlfarth C, Hovius R, Schmitteckert S, Röth R, Lasitschka F, Wink M,
Bönisch H, and Niesler B (2014) Natural compounds boldine and menthol are
antagonists of human 5-HT3 receptors: implications for treating gastrointestinal
disorders. Neurogastroenterol Motil 26:810–820.
Yip GM, Chen ZW, Edge CJ, Smith EH, Dickinson R, Hohenester E, Townsend RR,
Fuchs K, Sieghart W, and Evers AS, et al. (2013) A propofol binding site on
mammalian GABAA receptors identified by photolabeling. Nat Chem Biol 9:
715–720.
Ziemba PM, Schreiner BS, Flegel C, Herbrechter R, Stark TD, Hofmann T, Hatt H,
Werner M, and Gisselmann G (2015) Activation and modulation of recombinantly
expressed serotonin receptor type 3A by terpenes and pungent substances.
Biochem Biophys Res Commun 467:1090–1096.
Address correspondence to: Dr. Andrew J. Thompson, Department of
Pharmacology, Tennis Court Road, Cambridge CB2 1PD. E-mail: ajt44@cam.
ac.uk
562 Jarvis et al.
 at A
SPET Journals on D
ecem
ber 14, 2016
jpet.aspetjournals.org
D
ow
nloaded from
 
